|drug2948||SARS-CoV-2 S1/S2 IgG Wiki||0.71|
|drug2245||Non-interventional study Wiki||0.71|
|drug2807||Rapid Onsite COVID-19 Detection Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 2 clinical trials
This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).
Description: Rate of death from any causeMeasure: 30-day all-cause mortality Time: 30 day
Description: Rate of COVID-19 complicationsMeasure: COVID-19 complications Time: 30 day
Description: Rate of ICU admissionMeasure: ICU admission Time: 30 day
Description: Rate of mechanical ventilation / O2 requirementMeasure: Mechanical ventilation / O2 requirement Time: 30 day
Description: Rate of relapse or progression of hematologic diseaseMeasure: Relapse or progression of hematologic disease Time: 30 day, 90 day and 180 day
Description: Number of patients aliveMeasure: Overall survival Time: 30 day, 90 day and 180 day
Description: Putative risk factors for the severity and lethality of COVID-19Measure: Risk factors Time: 30 day, 90 day and 180 day
In Italy there are about 5000 patients with dependent transfusion thalassemia (source Italian Thalassemia and Hemoglobinopathies - SITE) and a smaller number, currently not definable, of patients with sickle cell anemia in chronic transfusion. A recent study in the Lombardy region identified the positivity of anti-Covid-19 antibodies in 4.5-7% of asymptomatic donors (Valenti L et al). As already known, a preliminary study conducted in Italy (Motta I et al, Hussain FA et al, Taher A et al) reported only 11 cases of symptomatic infection all with benign evolution. Currently there are 15 reported cases (12 thalassemias and 3 sickle cell anemias). 75% of the cases have been identified in Lombardy. Our hypothesis is that in a percentage of polytransfused patients a transmission of the virus may have developed that stimulated the production of protective antibodies. This could be an explanation of the low contagiousness and severity of the infection in polytransfused patients. Currently no data are available for this purpose. This study will be conducted in collaboration with the Microbiology Unit and involves the determination of SARS-CoV-2 antibodies (anti-s1 and s2) by CLIA method with a high sensitivity (94.7%) and specificity (98.5%).
Description: On the basis of the few data available in Italy, the investigator foresees 5-10% of positive subjects.Measure: Positive subjects Time: 2 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports